ストックスクリーナーアプリを入手
26.93
3.62%
0.94
アフターアワーズ：
26.82
-0.11
-0.41%
前日終値:
$25.99
開ける：
$26.09
24時間の取引高:
2.05M
Relative Volume:
1.10
時価総額：
$2.73B
収益：
$352.57M
当期純損益:
$-143.01M
株価収益率:
-14.88
EPS:
-1.81
ネットキャッシュフロー:
$-153.40M
1週間 パフォーマンス:
+8.90%
1か月 パフォーマンス:
-20.07%
6か月 パフォーマンス:
+59.73%
1年 パフォーマンス:
-5.74%
1日の値動き範囲:
$25.69
$27.02
1週間の範囲:
$25.21
$27.86
52週間の値動き範囲:
$13.53
$36.44
Beam Therapeutics Inc Stock (BEAM) Company Profile
名前
Beam Therapeutics Inc
セクター
電話
857-327-8775
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
26.93 | 2.64B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-09 | 開始されました | Jefferies | Buy |
| 2025-03-28 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-03-10 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-07-23 | 開始されました | H.C. Wainwright | Buy |
| 2024-01-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-12-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-08 | ダウングレード | Jefferies | Buy → Hold |
| 2023-10-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-02-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 開始されました | Citigroup | Buy |
| 2022-06-17 | 開始されました | BMO Capital Markets | Market Perform |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2022-01-05 | 開始されました | Guggenheim | Buy |
| 2021-10-19 | 開始されました | SVB Leerink | Outperform |
| 2021-09-24 | 再開されました | Stifel | Buy |
| 2021-09-10 | 開始されました | BofA Securities | Buy |
| 2021-05-11 | 開始されました | Redburn | Buy |
| 2021-05-04 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 開始されました | Wells Fargo | Overweight |
| 2021-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 開始されました | Stifel | Hold |
| 2020-08-05 | 開始されました | William Blair | Outperform |
| 2020-03-02 | 開始されました | Barclays | Overweight |
| 2020-03-02 | 開始されました | JP Morgan | Overweight |
| 2020-03-02 | 開始されました | Jefferies | Buy |
| 2020-03-02 | 開始されました | Wedbush | Outperform |
すべてを表示
Beam Therapeutics Inc (BEAM) 最新ニュース
Trading Recap: Can Beam Therapeutics Inc sustain its profitabilitySell Signal & AI Enhanced Trading Alerts - baoquankhu1.vn
Beam Therapeutics Secures Standby License for Key Patents - TipRanks
Buyout Rumor: Will Alector Inc stock hit new highs in YEAR2025 Valuation Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Volume Summary: What is Beam Therapeutics Incs debt to equity ratioJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - baoquankhu1.vn
Understanding Momentum Shifts in (BEAM) - Stock Traders Daily
Aug Reactions: What is Beam Therapeutics Incs debt to equity ratioJuly 2025 Fed Impact & Verified Technical Trade Signals - baoquankhu1.vn
FMR LLC's Strategic Acquisition of Beam Therapeutics Inc. Shares - GuruFocus
Beam Therapeutics Inc. (BEAM) Stock Analysis: A Biotech Innovator with 73% Potential Upside - DirectorsTalk Interviews
Beam Therapeutics Meets 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
Beam Therapeutics (NASDAQ:BEAM) Downgraded by Wall Street Zen to Sell - MarketBeat
Top CRISPR Companies for 2026 and How to Invest - The Motley Fool
IQ EQ FUND MANAGEMENT IRELAND Ltd Buys 188,243 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics announces upcoming board member resignation - TipRanks
Bear Alert: Can Beam Therapeutics Inc. sustain its profitability2025 Stock Rankings & Safe Entry Point Identification - baoquankhu1.vn
Beam Therapeutics Inc. (BEAM) Stock Analysis: A 69% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Beam Therapeutics: A Critical Year for Clinical Validation - AD HOC NEWS
Y Intercept Hong Kong Ltd Takes Position in Beam Therapeutics Inc. $BEAM - MarketBeat
Avoiding Lag: Real-Time Signals in (BEAM) Movement - Stock Traders Daily
Beam Therapeutics Senior Vice President Sells 6,198 Shares for $216,933 - Yahoo Finance
Privium Fund Management B.V. Acquires Shares of 61,000 Beam Therapeutics Inc. $BEAM - MarketBeat
Wall Street Zen Upgrades Beam Therapeutics (NASDAQ:BEAM) to Hold - MarketBeat
Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM) - Finviz
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
ARK Investment Acquires 116K Shares of Beam Therapeutics (BEAM) - GuruFocus
Beam Therapeutics Inc. (BEAM) Stock Analysis: A Look at the 46.90% Potential Upside and Cutting-Edge Genetic Medicine Advancements - DirectorsTalk Interviews
Christine Bellon Sells 1,371 Shares of Beam Therapeutics (NASDAQ:BEAM) Stock - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Shares Down 7.6%Here's Why - MarketBeat
Sickle Cell Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharma, Beam Therapeutics, Graphite Bio, Roche - Barchart.com
JonesTrading Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $35 - 富途资讯
William Blair Maintains Beam Therapeutics(BEAM.US) With Buy Rating - 富途资讯
Cathie Wood Sells Beam Therapeutics Stock, Buys WeRide and Tempus AI - Blockonomi
Cathie Wood Sells $5 Million Beam Therapeutics Stock, Buys WeRide and Tempus AI - CoinCentral
Campbell & CO Investment Adviser LLC Lowers Stock Position in Beam Therapeutics Inc. $BEAM - MarketBeat
Is Beam Therapeutics Inc forming a breakout pattern2025 Key Highlights & Free Community Consensus Stock Picks - baoquankhu1.vn
Beam soars 22% as FDA signs off on its ambitious gene-editing plan - MSN
Growth Report: Is Butterfly Network Inc Equity Warrant stock a buy or sellMarket Sentiment Summary & Advanced Technical Signal Analysis - baoquankhu1.vn
cathie wood’s ARK sells beam therapeutics stock, buys weride and tempus ai By Investing.com - Investing.com India
cathie wood’s ARK sells beam therapeutics stock, buys weride and tempus ai - Investing.com
Beam Therapeutics (NASDAQ:BEAM) Trading 11.1% HigherWhat's Next? - MarketBeat
Cathie Wood Dumps Beam Therapeutics, Loads Up on Netflix Stock - Blockonomi
Cathie Wood’s ARK ETFs Buy Netflix, Sell Beam Therapeutics in Latest Moves - CoinCentral
Beacon trial data makes Beam Therapeutics (BEAM) an attractive buy - MSN
Analysts’ Opinions Are Mixed on These Healthcare Stocks: TransMedics Group (TMDX), Beam Therapeutics (BEAM) and Boston Scientific (BSX) - The Globe and Mail
Insider Sell: Bethany Cavanagh Sells Shares of Beam Therapeutics Inc (BEAM) - GuruFocus
Beam Therapeutics (BEAM) Receives Rating Update with Raised Pric - GuruFocus
Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway By Investing.com - Investing.com India
Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway - Investing.com Nigeria
Discipline and Rules-Based Execution in BEAM Response - Stock Traders Daily
Insider Selling: Beam Therapeutics (NASDAQ:BEAM) Insider Sells 18,629 Shares of Stock - MarketBeat
SG Americas Securities LLC Purchases 36,004 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
JPM26: Beam, Cabaletta, More Zero In on Regulatory Alignment After Tumultuous Year - BioSpace
Beam Therapeutics Inc (BEAM) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):